The Uromigos

GU Oncology Now

During the second-annual Uromigos Live &amp; Unplugged event, Brian Rini, MD, FASCO; Michael Morris, MD; Rana McKay, MD; Tanya Dorff, MD; and Neeraj Agarwal, MD, discuss and deliberate on new data related to radioligand therapies in prostate cancer, including a recap of the VISION trial data and an in-depth look at the PSMAfore trial data, as well as how current practice patterns should be altered as a result of new understandings.The panel then goes over the PSMA-directed radioligand therapies expected in multiple indications within the next several years.View the <a href="https://guoncologynow.com/post/uromigos-live-2023-where-do-we-stand-with-parp-inhibitors-in-prostate-cancer" target="_blank" rel="noopener">first prostate cancer session</a> of the day on PARP inhibitors.

Uromigos Live 2023: Current and Future Status of Radioligand Therapy in Prostate Cancer

Uromigos Live 2023

The panel discusses data related to RLTs in prostate cancer, including a recap of the VISION trial and the PSMAfore trial.

Current, Future Status of Radioligand Therapy in Prostate Cancer

About Us

Contributors and Partners

Editorial Policy

Advertising

eNewsletters

Calendar

Contact Us

Contribute

MashupMD

Cancer Nursing Today

Urban Health Today

Blood Cancers Today

DocWire News

Knowledge Hubs

Conference Coverage

Roundtables

Uromigos Live 2024

AUC3

Localized

mHSPC/mCSPC

CRPC

Diagnostics

Prostate Cancer

Localized Renal Cell Carcinoma

Advanced Renal Cell Carcinoma

nccRCC

Renal Cell Carcinoma

Non-Muscle Invasive Urothelial Carcinoma

Muscle Invasive Urothelial Carcinoma

Advanced Urothelial Carcinoma

Upper Tract Urothelial Carcinoma

Urothelial Carcinoma

Testicular, Penile, and Rare Cancers

Video Insights

Advancements in Oncology

The Oncology Brothers

Expert Interviews

Journal

Subscribe